Brief: Verona Pharma Says NDA Submission On Schedule For Q2 2023
09/05/2023 07:10
May 9 (Reuters) - Verona Pharma Plc I9SAy.F :
* VERONA PHARMA REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
AND
PROVIDES CORPORATE UPDATE
* NDA SUBMISSION ON SCHEDULE FOR Q2 2023
Source text for Eikon: ID:nGNX7vJVGC
Further company coverage: I9SAy.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Verona Pharma
See all newsBrief: Acquisition Of Verona By Msd Approved By The High Court Of Justice Of England And Wales
Brief: Shareholders Of Verona Pharma Approve Proposed Acquisition By Merck
US corporate debt market returns in force after market holiday
Merck to cut jobs and costs as demand for Gardasil in China remains weak (updated)
Merck to cut jobs and costs as demand for Gardasil in China remains weak